Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023)
Genelux (GNLX) posted Total Non-Current Liabilities of $1.9 million for Q4 2023, up 44.76% on a QoQ basis from $1.3 million in Q3 2023, and down 80.74% year-over-year from $9.7 million in Q4 2022.
Powered by 
Analysis
Genelux (GNLX) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Genelux has reported Total Non-Current Liabilities for 2 years, with the latest figure at $1.9 million in Q4 2023.
- On a quarterly basis, Total Non-Current Liabilities fell 80.74% year-over-year to $1.9 million in Q4 2023; TTM through Dec 2023 was $1.9 million, a 80.74% decrease from a year earlier, with the FY2023 full-year figure at $1.9 million, down 80.74% from the prior year.
- Total Non-Current Liabilities was $1.9 million for Q4 2023 at Genelux, up from $1.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.7 million in Q4 2022, with the low at $1.3 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Dec 31, 2022 | 9.69 Mn |